Related Experiment Video
Updated: Jun 16, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
Cisplatin and ototoxicity in childhood: the perspective of supporting otoprotective agentes
A G F S Araujo1, J C Silva1, E M Trindade Filho1
1Universidade Estadual de Ciências da Saúde de Alagoas - UNCISAL, Maceió, AL, Brasil.
Insights
This review identifies eight substances that can protect against cisplatin-induced hearing loss in children. These otoprotective drugs act as antioxidants, minimizing auditory damage and improving quality of life.
Area of Science:
- Pharmacology and Toxicology
- Oncology
- Otolaryngology
Background:
- Cisplatin is a vital antineoplastic drug used to treat various cancers.
- A significant side effect of cisplatin is ototoxicity, leading to irreversible hearing loss, particularly impactful in pediatric patients due to its effect on language acquisition.
- Minimizing cisplatin-induced ototoxicity requires identifying effective otoprotective drugs and optimal administration strategies.
Purpose of the Study:
- To review and understand otoprotective drugs for preventive treatment against cisplatin-induced ototoxicity in childhood.
- To assess the relevance and potential of these drugs in mitigating hearing loss.
Main Methods:
- An integrative review was conducted using databases: PubMed, Bireme, MedLine, LILACS, SciELO, and ClinicalTrials.gov.
- Search strategy involved crossing DeCS and MeSH descriptors with free terms.
- Studies in English, Spanish, and Portuguese, with no publication year restrictions, were selected based on inclusion/exclusion criteria, resulting in 12 articles for full analysis.
Main Results:
- Eight substances demonstrated potential otoprotective effects against cisplatin-induced ototoxicity: Amifostine, Dexamethasone, Genistein, Ginkgo Biloba, Lycopene, N-acetylcysteine, Polydatin, and Sodium Thiosulfate.
- These drugs are administered via intravenous, oral, or transtympanic routes, before, during, or after cisplatin infusion.
- Biochemical mechanisms include inactivation of oxygen free radicals and electrophilic platinum species, acting as antioxidant therapy.
Conclusions:
- The identified substances show promise in reducing cisplatin-induced ototoxicity and subsequent hearing loss in children.
- Otoprotective strategies can significantly improve the quality of life for pediatric cancer patients undergoing cisplatin treatment.
- Further research into optimal drug combinations and administration protocols is warranted.
Abstract:
Cisplatin is an antineoplastic medicine used in the treatment for various types of cancer. Among its side effects is ototoxicity, which may result in a bilateral and irreversible hearing loss. The ototoxic effect in the pediatric population has a bigger impact as it compromises language acquisition. The discovery of drugs with otoprotective effects and the optimal way to administer them have become significant challenges in minimizing the impact of cisplatin regarding auditory function. The objective was to understand otoprotective drugs and their relevance in the preventive treatment to cisplatin-induced ototoxicity in childhood. An integrative review was conducted by consulting databases including PubMed, Bireme, MedLine, LILACS, SciELO, and ClinicalTrials.gov. The search strategy was performed by crossing descriptors (DeCS and MeSH) and free terms. Studies published in English, Spanish, and Portuguese were selected, with no publication year restrictions. Subsequently, articles were selected according to inclusion and exclusion criteria. A total of 736 articles were found in PubMed, 431 in Bireme, 425 in MedLine, 6 in LILACS, 0 in SciELO, and 4 in ClinicalTrials.gov. After document analysis, 12 articles were selected for full analysis. Evidence was found for 8 substances with potential otoprotective effects when used with cisplatin, which tend to minimize the impact of cisplatin regarding auditory function. The substances found were: Amifostine, Dexamethasone, Genistein, Ginkgo Biloba, Lycopene, N-acetylcysteine, Polydatin also Sodium Thiosulfate. In general, these drugs are applied before, during, or after cisplatin infusion, depending on the chosen drug, via intravenous, oral, or transtympanic injections, acting as antioxidant therapy. The biochemical effects of these substances are relevant to their potential otoprotective properties, including the inactivation of oxygen free radicals and electrophilic platinum species. The use of these substances can reduce ototoxicity, decreasing cisplatin-induced hearing loss and improving the confort of life, especially for children.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion

